Company Overview

Vanda Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for central nervous system disorders, sleep-related conditions, inflammatory diseases, and rare disorders. The company operates within the biotechnology and specialty pharmaceutical industries and generates revenue primarily from sales of approved prescription products and, to a lesser extent, licensing and collaboration arrangements. Its commercial portfolio has centered on therapies targeting neurological and psychiatric conditions, including circadian rhythm sleep disorders and schizophrenia-related indications.

The company’s principal marketed products include HETLIOZ® (tasimelteon), approved for non-24-hour sleep-wake disorder and certain circadian rhythm disorders, and Fanapt® (iloperidone), an antipsychotic approved for schizophrenia and bipolar disorder-related indications in the United States. Vanda has also advanced a pipeline spanning gastroenterology, neurology, ophthalmology, and immunology. Founded in 2002 and headquartered in Washington, D.C., the company evolved from a development-stage biotechnology firm into a commercial-stage pharmaceutical company following U.S. regulatory approvals and subsequent commercialization efforts. Public filings and investor materials consistently identify the company’s strategy as combining internally developed therapies with targeted lifecycle management and selective acquisition opportunities.

Business Operations

Vanda conducts operations primarily through a single integrated business structure focused on pharmaceutical development and commercialization. Revenue is derived mainly from U.S. product sales of HETLIOZ® and Fanapt®, supported by commercial sales infrastructure, physician outreach, payer engagement, and specialty pharmacy distribution networks. The company also invests heavily in clinical research and regulatory activities tied to new indications and pipeline candidates. Vanda’s intellectual property portfolio includes patents, formulation technologies, and regulatory exclusivities associated with its marketed and investigational compounds.

While the majority of commercial revenue has historically originated in the United States, Vanda has pursued international expansion through licensing arrangements, distribution partnerships, and regulatory filings in selected foreign markets. The company has maintained collaborations related to manufacturing, supply chain operations, and clinical development. Public disclosures also reference ownership or control of proprietary development programs involving compounds such as tradipitant and milsaperidone. Manufacturing activities are substantially outsourced to contract manufacturing organizations, a common structure among mid-cap biotechnology firms.

Strategic Position & Investments

Vanda’s strategic direction has emphasized maximizing the commercial potential of approved products while advancing late-stage clinical assets targeting unmet medical needs. A significant portion of corporate investment has been directed toward tradipitant, an investigational neurokinin-1 receptor antagonist studied across indications including gastroparesis, motion sickness, and dermatologic conditions. The company has also invested in expanding the approved uses of Fanapt® and HETLIOZ®, including pediatric and bipolar-related indications.

The company has periodically pursued acquisitions and licensing transactions to broaden its development portfolio. Notable transactions include the acquisition of rights associated with compounds such as Fanapt® and additional neuroscience-focused assets. Vanda’s positioning within specialty pharmaceuticals is supported by expertise in central nervous system therapeutics, orphan-drug commercialization, and regulatory strategy for niche patient populations. Public company filings indicate continued investment in clinical-stage programs and intellectual property protection intended to support long-term exclusivity and pipeline diversification.

Geographic Footprint

Vanda Pharmaceuticals Inc. is headquartered in Washington, D.C., United States, and maintains its primary commercial and administrative operations in the U.S. The company’s marketed products are principally sold in the American healthcare market, where it maintains relationships with healthcare providers, specialty pharmacies, distributors, and payers. Its operational infrastructure includes clinical trial management and regulatory affairs functions supporting both domestic and international development efforts.

Outside the United States, Vanda has pursued selective market access strategies in regions including Europe, Asia-Pacific, and parts of North America through regulatory submissions, licensing arrangements, and third-party commercialization relationships. International activity has primarily focused on product approvals, intellectual property management, and clinical research rather than large-scale direct commercial infrastructure. Publicly available disclosures indicate that the company evaluates international opportunities opportunistically based on regulatory pathways, reimbursement conditions, and market demand.

Leadership & Governance

Vanda was founded by Mihael H. Polymeropoulos, who has played a central role in shaping the company’s scientific and commercial strategy. Leadership communications and public filings emphasize a long-term approach focused on neuroscience innovation, targeted specialty commercialization, and internally driven research and development. Corporate governance is overseen by the board of directors and executive management in accordance with U.S. public company standards and reporting obligations under the SEC framework, including disclosures through Form 10-K, Form 10-Q, and proxy filings.

Key executives and leadership figures include:

• Mihael H. Polymeropoulos – President, Chief Executive Officer, and Chairman of the Board
• Kevin P. Moran – Senior Vice President, Chief Financial Officer, and Treasurer
• Timothy R. Williams – Senior Vice President, General Counsel, and Secretary
• Gunther Birznieks – Senior Vice President, Business Development
• Richard W. Kim – Vice President, Medical Affairs

Information regarding executive roles, product portfolio, operating structure, and strategic initiatives is consistently supported by company regulatory filings, investor presentations, and reporting from major financial and pharmaceutical industry publications. Where public disclosures differ in timing due to executive transitions or evolving pipeline programs, the most recently filed SEC disclosures provide the controlling reference point.